Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

710 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Atherogenic lipoprotein particles in atherosclerosis.
Carmena R, Duriez P, Fruchart JC. Carmena R, et al. Among authors: fruchart jc. Circulation. 2004 Jun 15;109(23 Suppl 1):III2-7. doi: 10.1161/01.CIR.0000131511.50734.44. Circulation. 2004. PMID: 15198959 Review.
HDL and triglyceride as therapeutic targets.
Fruchart JC, Duriez P. Fruchart JC, et al. Curr Opin Lipidol. 2002 Dec;13(6):605-16. doi: 10.1097/00041433-200212000-00003. Curr Opin Lipidol. 2002. PMID: 12441884 Review.
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Després JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nuñez-Cortes JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner Ž, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokgözoğlu LS, Tomlinson B, Tybjærg-Hansen A, Valensi P, Vrablík M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P. Fruchart JC, et al. Cardiovasc Diabetol. 2019 Jun 4;18(1):71. doi: 10.1186/s12933-019-0864-7. Cardiovasc Diabetol. 2019. PMID: 31164165 Free PMC article. Review.
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
Tailleux A, Duriez P, Fruchart JC, Clavey V. Tailleux A, et al. Among authors: fruchart jc. Atherosclerosis. 2002 Sep;164(1):1-13. doi: 10.1016/s0021-9150(01)00751-1. Atherosclerosis. 2002. PMID: 12119188 Review.
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators. Deedwania P, et al. Among authors: fruchart jc. Lancet. 2006 Sep 9;368(9539):919-28. doi: 10.1016/S0140-6736(06)69292-1. Lancet. 2006. PMID: 16962881 Clinical Trial.
Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression.
Tailleux A, Gozzo A, Torpier G, Martin-Nizard F, Bonnefont-Rousselot D, Lemdani M, Furman C, Foricher R, Chevé G, Yous S, Micard F, Bordet R, Gardes-Albert M, Lesieur D, Teissier E, Fruchart JC, Fiévet C, Duriez P. Tailleux A, et al. Among authors: fruchart jc. J Cardiovasc Pharmacol. 2005 Sep;46(3):241-9. doi: 10.1097/01.fjc.0000175232.11079.7e. J Cardiovasc Pharmacol. 2005. PMID: 16116326
710 results